| scholarly article | Q13442814 |
| P50 | author | Willem Weimar | Q64124006 |
| Teun van Gelder | Q87686764 | ||
| P2093 | author name string | Jan Lindemans | |
| Ilse P van der Heiden | |||
| Ron H N van Schaik | |||
| Dennis A Hesselink | |||
| Peter J H Smak Gregoor | |||
| Marloes van der Werf | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cyclosporine | Q367700 | ||
| P304 | page(s) | 245-254 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus | |
| P478 | volume | 74 |
| Q39041618 | A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach |
| Q47336853 | A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation |
| Q50764327 | A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. |
| Q42614831 | A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient |
| Q44962609 | A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients |
| Q35826448 | A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system |
| Q43282035 | A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients |
| Q53706894 | A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. |
| Q37161904 | A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients |
| Q36720915 | ABCB1 pharmacogenetics: progress, pitfalls, and promise |
| Q43598370 | ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients |
| Q92531843 | ASP1126, a Novel Sphingosine-1-Phosphate-Selective Agonist With a Favorable Safety Profile, Prolongs Allograft Survival in Rats and Nonhuman Primates in Combination With Tacrolimus With a Broad Safety Margin for Bradycardia |
| Q48853070 | ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. |
| Q35946398 | African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients |
| Q36806652 | Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients |
| Q40433411 | Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects |
| Q28083408 | Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS |
| Q55920371 | Ambroxol induces autophagy and potentiates Rifampin antimycobacterial activity |
| Q33850686 | Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs |
| Q37630718 | Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients |
| Q50522192 | Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. |
| Q57500309 | Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects |
| Q37140638 | Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen |
| Q81660032 | Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients |
| Q50635804 | Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients. |
| Q41994948 | Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation. |
| Q34653610 | CYP2D6 genotype dependent oxycodone metabolism in postoperative patients |
| Q48172244 | CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study |
| Q37478703 | CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation |
| Q33785147 | CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease |
| Q89585264 | CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel |
| Q46136739 | CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients |
| Q38068539 | CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy |
| Q46174193 | CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients |
| Q56834660 | CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study |
| Q43087572 | CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. |
| Q80316046 | CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients |
| Q43172642 | CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition |
| Q36704223 | CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition |
| Q43946040 | CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir |
| Q52921101 | CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. |
| Q79456645 | CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients |
| Q44819549 | CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. |
| Q55280859 | CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. |
| Q38241677 | Calcineurin inhibitors and hypertension: a role for pharmacogenetics? |
| Q36305439 | Cancer treatment and pharmacogenetics of cytochrome P450 enzymes |
| Q35016679 | Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation |
| Q35871392 | Characteristics of successful recruitment in prospective pediatric pharmacogenetic studies |
| Q64885429 | Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. |
| Q36613862 | Clinical application of pharmacogenetics in gastrointestinal diseases |
| Q54266810 | Clinical aspects of tacrolimus use in paediatric renal transplant recipients. |
| Q38748975 | Clinical determinants of calcineurin inhibitor disposition: a mechanistic review |
| Q37527189 | Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs |
| Q37678060 | Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. |
| Q36546247 | Clinical implications of CYP3A polymorphisms |
| Q36120833 | Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. |
| Q34332261 | Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation |
| Q46246088 | Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. |
| Q45921158 | Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. |
| Q45262234 | Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy |
| Q37724512 | Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study |
| Q36050572 | Cytochrome P450 3A polymorphisms and immunosuppressive drugs |
| Q37074093 | Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update |
| Q82577163 | Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients |
| Q92678415 | Dasatinib-induced nephrotic syndrome: a case of phenoconversion |
| Q33574176 | Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach |
| Q45420475 | Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro |
| Q36287737 | Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation |
| Q43791088 | Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? |
| Q44554143 | Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study |
| Q36326210 | Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation? |
| Q35629782 | Dosing equation for tacrolimus using genetic variants and clinical factors |
| Q43059203 | Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome? |
| Q38377264 | Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients |
| Q39634880 | Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation |
| Q57174194 | Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice? |
| Q34511457 | Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients |
| Q28073025 | Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature |
| Q34099716 | Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. |
| Q47920373 | Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre |
| Q38247190 | Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. |
| Q56834587 | Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients |
| Q37727968 | Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects |
| Q34255499 | Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients |
| Q46307844 | Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem |
| Q85964857 | Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants |
| Q53581879 | Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. |
| Q84208214 | Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus |
| Q37038199 | Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation |
| Q51693404 | Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. |
| Q54576089 | Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. |
| Q36654010 | Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors |
| Q35650886 | Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis |
| Q46795537 | Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs. |
| Q37587527 | Electronic health record design and implementation for pharmacogenomics: a local perspective |
| Q46676250 | Estrogen-metabolizing gene polymorphisms and lipid levels in women with different hormonal status. |
| Q39374368 | Ethnic differences in the distribution of CYP3A5 gene polymorphisms |
| Q42910524 | Evaluation of cinacalcet HCl treatment after kidney transplantation |
| Q34580586 | Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients |
| Q33847140 | Explaining variability in ciclosporin exposure in adult kidney transplant recipients |
| Q33849108 | Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach |
| Q42754368 | Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. |
| Q99708872 | Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation |
| Q54455073 | Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. |
| Q34550483 | Functional interactions between P-glycoprotein and CYP3A in drug metabolism |
| Q28260518 | Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests |
| Q38104742 | Genes and beans: pharmacogenomics of renal transplant |
| Q87268379 | Genetic determinants of renal transplant outcome: where do we stand? |
| Q36969067 | Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study |
| Q37218129 | Genetic polymorphisms and the fate of the transplanted organ |
| Q46420441 | Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus |
| Q30341330 | Genetic variability in CYP3A5 and its possible consequences. |
| Q37009025 | Genotype-guided tacrolimus dosing in African-American kidney transplant recipients |
| Q37803415 | How genetic variation affects patient response and outcome to therapy for psoriasis |
| Q45749580 | Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. |
| Q90450269 | Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study |
| Q36029868 | Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome |
| Q46149716 | Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors |
| Q37772515 | Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant |
| Q49917136 | Impact of Acute Infection Requiring Hospitalization on Tacrolimus Blood Levels in Kidney Transplant Recipients. |
| Q46063082 | Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India |
| Q45279289 | Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism |
| Q38414396 | Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature |
| Q36183911 | Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. |
| Q35827797 | Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition |
| Q47895423 | Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients |
| Q89435939 | Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations |
| Q35918055 | Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials |
| Q47292609 | In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. |
| Q48088487 | Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study |
| Q98725976 | Influence CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients |
| Q37397805 | Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. |
| Q54353014 | Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. |
| Q37063883 | Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile |
| Q46716764 | Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression |
| Q39816513 | Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. |
| Q46690564 | Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation |
| Q42795568 | Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients |
| Q57269486 | Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients |
| Q89511371 | Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients |
| Q90737574 | Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation |
| Q40265172 | Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. |
| Q79939096 | Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients |
| Q28244228 | Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients |
| Q34012749 | Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART |
| Q35987461 | Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects |
| Q45958453 | Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. |
| Q35943046 | Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function |
| Q34261356 | Itraconazole and domperidone: a placebo-controlled drug interaction study |
| Q46492467 | Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers |
| Q36803391 | Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients |
| Q44839090 | Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients. |
| Q36442886 | Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs |
| Q33683838 | Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. |
| Q36120816 | Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. |
| Q46606824 | Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients |
| Q36024688 | Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients |
| Q34197418 | Modeling chemical interaction profiles: I. Spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome P450 CYP3A4 and CYP2D6 isozymes |
| Q54396812 | Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype. |
| Q33268368 | Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. |
| Q36630081 | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium |
| Q37938905 | Overview of pharmacogenetics |
| Q50085603 | PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. |
| Q28082746 | Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine |
| Q33989902 | PharmGKB summary: cyclosporine and tacrolimus pathways |
| Q50940396 | Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. |
| Q38787174 | Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations |
| Q37439873 | Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients |
| Q36544981 | Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy |
| Q37768070 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. |
| Q37201611 | Pharmacogenetic treatments for drug addiction: alcohol and opiates. |
| Q50802111 | Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. |
| Q38435024 | Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients |
| Q38253383 | Pharmacogenetics and immunosuppressive drugs in solid organ transplantation |
| Q38258677 | Pharmacogenetics and immunosuppressive drugs. |
| Q46850642 | Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation |
| Q36916904 | Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation |
| Q37608121 | Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes |
| Q38063426 | Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. |
| Q37218086 | Pharmacogenetics in solid organ transplantation: current status and future directions |
| Q38120290 | Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs |
| Q37205946 | Pharmacogenetics of Crohn's disease |
| Q57163492 | Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients |
| Q43155487 | Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients |
| Q37157896 | Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q46986763 | Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies |
| Q36901492 | Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q36415330 | Pharmacogenomics and lung transplantation: clinical implications |
| Q28083875 | Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population |
| Q38983589 | Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. |
| Q37419542 | Pharmacogenomics of CYP3A: considerations for HIV treatment |
| Q36634077 | Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem |
| Q37818148 | Pharmacokinetic interactions between etravirine and non-antiretroviral drugs |
| Q36006086 | Pharmacokinetic principles of immunosuppressive drugs. |
| Q38520159 | Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. |
| Q53093221 | Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. |
| Q36471782 | Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants |
| Q47554956 | Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. |
| Q37662607 | Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. |
| Q34609009 | Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf |
| Q43253108 | Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. |
| Q36036364 | Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy |
| Q31097010 | Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations |
| Q64111320 | Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models |
| Q38115004 | Potential food-drug interactions in patients with rheumatoid arthritis |
| Q38133294 | Practicability of pharmacogenetics in transplantation medicine |
| Q45137094 | Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes |
| Q80259910 | Prediction of systemic exposure to cyclosporine in Japanese pediatric patients |
| Q45369421 | Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. |
| Q61047815 | Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit |
| Q36072508 | Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit |
| Q36761340 | Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation |
| Q34278794 | Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition |
| Q41566058 | Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation |
| Q39287053 | Renal transplantation in emigrants from Africa in Spain: similar results but different infectious profile compared with Spanish people. |
| Q36000874 | Renal transplantation, immunosuppression and the skin: an update |
| Q33606025 | Revealing phenotype-associated functional differences by genome-wide scan of ancient haplotype blocks |
| Q93089155 | Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis |
| Q34454797 | Role of pharmacogenomics in dialysis and transplantation |
| Q36375323 | Significance of the minor cytochrome P450 3A isoforms. |
| Q86974828 | Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases |
| Q46511487 | Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients |
| Q54435691 | Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. |
| Q40278149 | Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients |
| Q48276802 | Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model |
| Q37066299 | Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima |
| Q41622844 | Tacrolimus Aggravated Tube Feeding Syndrome with Acute Renal Failure in a Pediatric Liver Transplant Recipient |
| Q88726021 | Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients |
| Q42215557 | Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation |
| Q43187743 | Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics |
| Q35012176 | Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients |
| Q43061696 | Tacrolimus prolonged release in kidney transplantation |
| Q38901998 | Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: effect of post-transplantation period. |
| Q47803890 | The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. |
| Q38299085 | The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis |
| Q47306662 | The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients |
| Q37513374 | The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy |
| Q90136673 | The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? |
| Q33665154 | The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. |
| Q35618156 | The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients |
| Q79781706 | The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients |
| Q37024001 | The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. |
| Q46513372 | The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice |
| Q58812374 | The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients |
| Q37405437 | The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans |
| Q50868889 | The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. |
| Q47318084 | The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function |
| Q44899003 | The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. |
| Q35544537 | The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation |
| Q37722744 | The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. |
| Q36186945 | The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? |
| Q36286418 | The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. |
| Q39822576 | The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity. |
| Q36513703 | The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients |
| Q37981892 | The role of pharmacogenetics in nonmalignant gastrointestinal diseases |
| Q38163945 | The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. |
| Q35612903 | The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients |
| Q42837771 | Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients |
| Q42795566 | Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients |
| Q60935379 | Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients |
Search more.